Trials / Completed
CompletedNCT01592084
Hyperlipidemia and Statin Therapy in Amyotrophic Lateral Sclerosis
Cohort Study of the Relationship of Hyperlipidemia and Statin Therapy on Survival and Disease Progresssion in Amyotrophic Lateral Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 267 (actual)
- Sponsor
- The Methodist Hospital Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The role of hyperlipidemia and lipid lowering therapy (LLT) in Amyotrophic Lateral Sclerosis (ALS) pathophysiology and its impact on disease progression and survival is unclear. The investigators analyzed the correlation between lipid levels with disease progression and survival in ALS patients and the association of LLT with these outcomes.
Conditions
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2012-05-07
- Last updated
- 2012-05-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01592084. Inclusion in this directory is not an endorsement.